Hypertension Clinical Trial
Official title:
Blueberry Consumption for Improving Vascular Endothelial Dysfunction in Postmenopausal Women With Elevated Blood Pressure and Stage 1-Hypertension
Verified date | September 2022 |
Source | Colorado State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postmenopausal women are at an increased risk of developing cardiovascular disease (CVD) largely due to accelerated aging-related modifications to vascular health following menopause. The vascular endothelium is responsible for producing chemicals that are essential for proper vasodilation and blood flow and therefore is involved in maintaining normal blood pressure. A major modification that occurs during aging and is accelerated during menopause is termed vascular endothelial dysfunction which is characterized by impaired endothelium-dependent dilation. This can lead to increased blood pressure, atherosclerosis, and increased risk of CVD and death. Nitric oxide (NO) is a chemical produced by the endothelium and is essential for normal endothelial function and cardiovascular health. Vascular endothelial dysfunction is primarily caused by reduced NO bioavailability secondary to excessive oxidative stress. Approximately 3/4 of postmenopausal women have elevated blood pressure or hypertension which further worsens endothelial function and increases CVD risk through increased oxidative stress and inflammation. Blueberries are rich in phytochemicals including anthocyanins, phenolic acids, and pterostilbene. These phytochemicals and their metabolites are known to attenuate oxidative stress and inflammation. The overall goal of the current study is to assess the efficacy of blueberries to improve vascular endothelial dysfunction in this high-risk population and to gain insight into underlying mechanisms. 58 postmenopausal women with elevated blood pressure and stage 1-HTN will be asked to consume 22 grams freeze-dried blueberry powder or placebo powder per day for 12 weeks. Vascular endothelial function will be assessed at baseline and 12 weeks. Measurements indicative of vascular nitric oxide production, oxidative stress, inflammation, cardiometabolic health, cognitive function, and blueberry phytochemical metabolism will be measured at baseline and 12 weeks. Blood pressure will be assessed at baseline and 4, 8, and 12 weeks.
Status | Completed |
Enrollment | 43 |
Est. completion date | September 30, 2021 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 45 Years to 65 Years |
Eligibility | Inclusion Criteria: - Aged 45-65 years - Postmenopausal women (= 1 years postmenopausal; natural or surgical menopause; confirmed by measurement of estradiol at a level < 30 pg/mL and follicle-stimulating hormone at a level = 30 mIU/mL) - Elevated or stage 1-HTN (confirmed as resting seated systolic blood pressure < 120 or = 139 mmHg and/or a diastolic blood pressure = 90 mmHg using an average of 3 measurements, on 2 separate occasions - screening and baseline visits) - Ability to provide informed consent Exclusion Criteria: - Systolic blood pressure < 120 or = 139 mm Hg and/or diastolic blood pressure = 90 mmHg - Taking > 1 antihypertensive medication and/or taking the antihypertensive medication for < 3 months - Diagnosed cancer, cardiovascular disease, diabetes, or gastrointestinal, kidney, liver, and/or pancreatic disease - Triglycerides > 350 mg/dL, low-density lipoprotein cholesterol (LDL-C) = 190 mg/dL, and/or taking a lipid-lowering medication - Hormone replacement therapy use 6 months prior to study start - Taking phosphodiesterase-5 inhibitors - Weight change = 3 kg in the past 3 months, actively trying to lose weight, or unwilling to remain weight stable throughout the study - Current smokers or history of smoking in the past 12 months - Binge and/or heavy drinker (>3 drinks on any given occasion and/or >7 drinks/week for women, and >4 drinks on any given occasion and/or >14 drinks/week for men) - Body mass index < 18.5 or > 40 kg/m2 - Active infection or antibiotic therapy - Allergies or contraindication to study treatments, pharmacological agents, or procedures |
Country | Name | City | State |
---|---|---|---|
United States | Department of Food Science and Human Nutrition, Colorado State University | Fort Collins | Colorado |
Lead Sponsor | Collaborator |
---|---|
Colorado State University | U.S. Highbush Blueberry Council |
United States,
Johnson SA, Figueroa A, Navaei N, Wong A, Kalfon R, Ormsbee LT, Feresin RG, Elam ML, Hooshmand S, Payton ME, Arjmandi BH. Daily blueberry consumption improves blood pressure and arterial stiffness in postmenopausal women with pre- and stage 1-hypertension: a randomized, double-blind, placebo-controlled clinical trial. J Acad Nutr Diet. 2015 Mar;115(3):369-377. doi: 10.1016/j.jand.2014.11.001. Epub 2015 Jan 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Processing speed | Exploratory measures assessed using the NIH Cognitive Toolbox iPad app | Baseline and 12 weeks | |
Other | Language | Exploratory measures assessed using the NIH Cognitive Toolbox iPad app | Baseline and 12 weeks | |
Other | Working memory | Exploratory measures assessed using the NIH Cognitive Toolbox iPad app | Baseline and 12 weeks | |
Other | Executive function and attention | Exploratory measures assessed using the NIH Cognitive Toolbox iPad app | Baseline and 12 weeks | |
Other | Episodic memory | Exploratory measures assessed using the NIH Cognitive Toolbox iPad app | Baseline and 12 weeks | |
Other | Peripheral blood mononuclear cell inflammation and oxidative stress | Exploratory measures analyzed by gene expression | Baseline and 12 weeks | |
Primary | Endothelium-dependent dilation | Assessed as brachial artery flow-mediated dilation in a study subset of participants | Baseline to 12 Weeks | |
Primary | Blood pressure | Assessed using an automated blood pressure monitor (SphgmoCor) | Baseline to 12 weeks | |
Secondary | Vascular oxidative stress | Change in brachial artery flow-mediated dilation following acute infusion of ascorbic acid (a dose known to scavenge superoxide) as an index of vascular oxidative stress in a study subset of participants | Baseline and 12 weeks | |
Secondary | Endothelial cell nitric oxide production, oxidative stress, and inflammation | Protein expression markers will be measured by quantitative immunofluorescence in biopsied venous endothelial cells in a study subset of participants | Baseline and 12 weeks | |
Secondary | Systemic markers of cardiometabolic health | Circulating markers of lipid and glucose metabolism, nitric oxide, and inflammation | Baseline and 12 weeks | |
Secondary | Plasma blueberry polyphenol metabolites | Targeted analysis of plasma metabolites by GC-MS and LC-MS | Baseline and 12 weeks | |
Secondary | Endothelium-independent dilation | Assessed as brachial artery diameter responses to sublingual nitroglycerin in a study subset of participants | Baseline to 12 weeks | |
Secondary | Augmentation index | Arterial stiffness assessed as augmentation index using the SphygmoCor XCEL | Baseline to 12 weeks | |
Secondary | Pulse wave velocity | Arterial stiffness assessed as carotid-femoral pulse wave velocity using the SphygmoCor XCEL | Baseline to 12 weeks | |
Secondary | Gut microbiota | Determine the effects on stool sample microbial populations | Baseline to 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |